M

Merck

Makes medicines, vaccines and animal treatments

Facilities Specialist R&D

Full-TimePosted on 10/20/2026Deadline 11/10/26
No salary listed
Mid
Bachelor's
Boxmeer, Netherlands
In Person
Facilities OperationsFacilities Management

About the job

Requirements
  • A completed hbo-level education, preferably in Facility Management, Technical, Life Sciences, or a comparable field.
  • Experience coordinating facility, technical, or operational processes in a complex or regulated environment.
  • Knowledge of quality, compliance, and EHS processes; experience with audits, CAPAs, deviations, and change controls is an advantage.
  • Good command of Dutch and English, both spoken and written.
  • A structured and proactive working style, with attention to priorities, risks, and continuous improvement.
  • An analytical and practical approach, with the ability to translate issues into workable solutions.
  • A service-oriented mindset and ownership of work quality and collaboration.
Responsibilities
  • Coordinate and optimize facility processes, systems, installations, and operational activities within R&D.
  • Act as the point of contact, process coordinator, and subject matter expert for assigned facility topics.
  • Translate business, quality, compliance, and regulatory requirements into effective processes and working practices.
  • Ensure the availability, safety, and compliance of buildings, laboratories, utilities, and supporting facilities.
  • Coordinate maintenance shutdowns and planned work, and align activities among internal and external stakeholders.
  • Prepare, maintain, and improve standard operating procedures, work instructions, quality documentation, training materials, and user communications.
  • Represent Facilities during audits, inspections, deviations, corrective and preventive actions, and change controls.
  • Provide facility expertise and input for capital expenditure projects, including risk analyses, user needs, and operational impact.
  • Identify and escalate risks, bottlenecks, and capacity issues in a timely manner.
  • Contribute to continuous improvement and a safe, reliable, and future-ready R&D environment.
Desired Qualifications
  • Knowledge of quality, compliance, and EHS processes; experience with audits, CAPAs, deviations, and change controls is an advantage.
  • A completed hbo-level education in Facility Management, Technical, Life Sciences, or a comparable field is preferred.

About the company

Merck develops prescription medicines, vaccines and veterinary treatments for patients, health systems and animal owners worldwide. Its vaccine portfolio includes Gardasil 9, which helps prevent cancers and other diseases caused by several types of human papillomavirus. The company takes potential treatments through laboratory research and clinical trials, then manufactures and sells approved products to drug distributors, hospitals, physicians and governments. Its animal health division sells medicines and vaccines to veterinarians, farmers and pet owners, while selected drug partnerships also earn shared profits or royalties. Founded in 1891, Merck is headquartered in Rahway, New Jersey.

Company Size

10,001+

Company Stage

IPO

Headquarters

Rahway, New Jersey

Founded

1891

Get referred to Merck

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • U.S. employees build retirement benefits: Merck pairs a defined benefit pension with a matching 401(k).
  • Scientists work within a large research network: Merck reports approximately 24,700 employees in R&D.
  • Animal health adds growth: August 2026 results report Q2 sales of $1.8 billion, up 8% year over year.

What critics are saying

  • Job security faces cuts: Merck's active restructuring program eliminates roles and shrinks its global real estate footprint.
  • Keytruda protection narrows: its main U.S. patent expires in 2028, with additional patents expiring in 2029.
  • Revenue is concentrated: August 2026 results show Keytruda products generated $8.4 billion of Merck's $16.6 billion Q2 sales.

What makes Merck unique

  • Merck extends into farm technology: SenseHub continuously monitors livestock for behavioral and physiological changes.
  • Merck publishes open medical knowledge: its Manuals give clinicians and patients free online references.
  • Merck's donation commitment is open-ended: Mectizan supplies for river blindness continue for as long as needed.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

-19%

1 year growth

-20%

2 year growth

-20%
Yahoo Finance
Oct 21st, 2026
Keytruda is half of Merck's $16.6B quarterly sales, so what if growth stalls?

Merck's Keytruda cancer drug family generated $8.4 billion in fiscal Q2 2026, about half of the company's $16.6 billion revenue. Excluding currency, Keytruda sales grew 4%, the same pace as total revenue. Management said on the August 4 call that US Keytruda growth will moderate as the drug reaches peak penetration. A Dutch court has also barred Merck from selling subcutaneous Keytruda in eight European markets, Barron's reported. Newer drugs are growing faster. WINREVAIR sales rose 75% to $588 million, and WELIREG sales rose 67%. Free cash flow of $16.1 billion covered dividends of $8.3 billion about twice. Total debt rose to $53.9 billion from $35.4 billion a year earlier. Merck is expected to report results on October 29.

Ash
Oct 20th, 2026
Ash announces $10M Series A funding to uplevel at-home health testing to close healthcare gaps for millions

Ash secures $10M Series A funding led by Merck GHI Fund. We are scaling at home lab test programs to close care gaps and bring patients into the care cycle.

CNBC
Oct 20th, 2026
Trump administration reaches diesel supply agreement with Russia ahead of US midterm elections.

Trump administration reaches diesel supply agreement with Russia ahead of US midterm elections. US President Donald Trump and Russian President Vladimir Putin have reached an agreement to release Russian diesel fuel into American and international markets in an effort to lower energy prices before November's midterm elections. The arrangement has drawn scrutiny over its implications for sanctions against Russia and the continuing war in Ukraine. Iranian Forces Target Strait of Hormuz Shipping in Reported Effort to Influence US Elections Iranian military and allied forces are reportedly using new tactics against commercial shipping in the Strait of Hormuz, with the stated aim of driving up global oil prices and increasing political pressure ahead of the US midterm elections. The activity raises concerns about maritime security and energy supplies along a critical international shipping route. Federal Judge Extends Order Protecting White House Access for CNN, Politico and MS NOW A US federal judge has extended a preliminary injunction preventing the Trump administration from revoking White House press credentials held by reporters from CNN, Politico and MS NOW. The ruling preserves journalists' access while recognizing the government's authority to protect classified national security information. US Regulators Fine Bank of America $1.2 Billion Over Financial Compliance Failures Federal regulators have imposed a $1.2 billion penalty on Bank of America over failures to monitor and report suspicious financial activity. The enforcement action focuses on shortcomings in the bank's compliance procedures and underscores regulatory scrutiny of financial crime prevention. US Justice Department Investigates Suspected Espionage Device Found in OpenAI Conference Room Federal investigators are examining an encrypted recording device reportedly discovered inside a television in an executive conference room at OpenAI. The investigation centers on potential corporate espionage and raises questions about the security of sensitive information within the artificial intelligence company. Trump Suggests Canada Could Become 51st US State, Drawing Canadian Opposition US President Donald Trump has suggested during a campaign rally in San Antonio, Texas, that Canada could eventually become America's 51st state, citing trade relations between the two countries. The remarks prompted objections from Canadian officials and renewed diplomatic controversy. US Ambassador Kimberly Guilfoyle Resigns From Post in Greece Following White House Request Kimberly Guilfoyle has resigned as US ambassador to Greece after the White House requested her departure following a series of damaging reports. Her resignation leaves the State Department seeking new leadership for its diplomatic mission in Athens. Merck Opens $550 Million Pharmaceutical Research Facility in Pennsylvania US pharmaceutical company Merck has inaugurated a $550 million bioanalytical research and development facility in West Point, Pennsylvania. The investment expands the company's domestic research infrastructure and supports advanced pharmaceutical development in the region.

Yahoo Finance
Oct 19th, 2026
Merck and AbbVie shares jump 39% and 24% in 2026 as dividend picks for a decade

Healthcare stocks are rebounding in 2026, led by Merck and AbbVie. Merck shares have climbed 39% and AbbVie's 24%, against about 12% for the S&P 500. Merck's second-quarter revenue rose 5% to $16.6 billion, beating Wall Street estimates. Keytruda sales hit $8.4 billion, though the drug will likely lose patent exclusivity by 2028. A subcutaneous version, Keytruda Qlex, may help retain market share. Merck's forward dividend yield is 2.3%. AbbVie's revenue grew 10.2% to almost $17 billion, with adjusted earnings per share up 22.9% to $3.65. Skyrizi and Rinvoq sales each rose about 24%, and neither faces US competition until 2033 and 2037 respectively. AbbVie has raised its dividend for 54 straight years, including its time as part of Abbott Laboratories.

Benzinga
Oct 19th, 2026
What's going on with Moderna stock Monday?

What's going on with Moderna stock Monday? Stock score locked: want to see it? Benzinga Rankings give you vital metrics on any stock - anytime. Moderna Inc. (NASDAQ:MRNA) shares are trading higher Monday as investors position ahead of detailed Phase 3 melanoma data for its personalized cancer therapy this Saturday and after BofA raised its price target. Traders move into Moderna ahead of Saturday's Phase 3 melanoma data at ESMO. According to Investing.com, the main driver is Saturday's Presidential Symposium at the ESMO Congress in Madrid, where Moderna and Merck will present full results from the Phase 3 INTerpath-001 trial at 10:30 a.m. ET on Oct. 24. The trial tested intismeran autogene plus Keytruda against Keytruda alone in 1,137 patients with resected stage IIB-IV melanoma. In August, the partners said it met its endpoints of recurrence-free and distant metastasis-free survival but didn't release detailed results, including overall survival. Moderna will host an investor webcast at 1 p.m. ET the same day. Jefferies expects peak unadjusted sales in melanoma alone to top $3 billion. BofA raises its target, and the stock rebounds from Friday's drop off its 52-week high. BofA raised its price target on Moderna to $220 from $200 and kept a Neutral rating. The stock is also rebounding after falling nearly 10% Friday from its 52-week high of $242.29, a drop attributed to profit-taking after a rally of more than 600% this year. Investing.com said the stock's addition to the Nasdaq-100 on October 9 continues to support shares through demand from index funds, and that BioNTech and Pfizer were broadly flat, which suggests the move is specific to Moderna and not a sector rotation. The broader market was also higher, with the Nasdaq up about 1% and the S&P 500 up about half a percent. Moderna reports third-quarter results November 6. Moderna shares climb higher. MRNA Price Action: At the time of publication, Moderna shares are trading 4.40% higher at $227.61, according to data from Benzinga Pro. This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors. Posted In: Beat The Market With Premarket News and Trade Signals